ACE and diabetes mellitus: The Diabetes REduction Assesment with ramipril and rosiglitazone Medication (DREAM) trial reported that RAAS blockade with the ACE inhibitor ramipril can not alter renal outcome in patients with impaired glucose tolerance and/or impaired fasting glucose levels [81], while the same study confirmed that the TZD-type PPARγ ligand rosiglitazone reduces diabetic kidney complications.